Literature DB >> 22855160

Reduced expression of Raf kinase inhibitor protein correlates with poor prognosis in pancreatic cancer.

Shi-peng Song1, Sheng-bin Zhang, Zhe-hai Li, Yong-sheng Zhou, Bing Li, Zhan-wei Bian, Qian-de Liao, Yang-de Zhang.   

Abstract

AIM: Raf kinase inhibitory protein (RKIP) is an inhibitor of the Raf/MEK/MAP kinase signaling cascade and a suppressor of cancer metastasis. But its function in pancreatic cancer was not yet clarified completely. The aim of this study was to investigate the involvement of RKIP in pancreatic cancer.
METHODS: RKIP expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumor tissue samples from a series (n = 99) of consecutive patients with pancreatic cancer. Survival was calculated using Kaplan-Meier curves. Parameters found to be of prognostic significance in univariate analysis were verified in a multivariate Cox regression model.
RESULTS: RKIP expression was high in normal pancreatic epithelium and retained to varying degrees in pancreatic cancer tissues. However, in tumor tissues with lymph node metastasis (P = 0.008) and high UICC stage (P = 0.006), RKIP expression was highly significantly reduced or lost. Furthermore, the reduced expression of RKIP significantly correlated with both poor overall and disease-free survival (P = 0.008 and 0.01, respectively). Multivariate analyses revealed RKIP to be an independent prognosticator.
CONCLUSION: These findings suggest that RKIP could be a promising marker for predicting a better prognosis in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855160     DOI: 10.1007/s12094-012-0870-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  17 in total

1.  Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines.

Authors:  Eiko Hayashi; Yasuhiro Kuramitsu; Futoshi Okada; Masanori Fujimoto; Xiulian Zhang; Masanobu Kobayashi; Norio Iizuka; Yoshiya Ueyama; Kazuyuki Nakamura
Journal:  Proteomics       Date:  2005-03       Impact factor: 3.984

2.  Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma.

Authors:  Hyun Soo Kim; Gou Young Kim; Sung-Jig Lim; Yong-Koo Park; Youn Wha Kim
Journal:  Hum Pathol       Date:  2010-08-04       Impact factor: 3.466

3.  Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.

Authors:  Hong Zhao Li; Yue Wang; Yan Gao; Jie Shao; Xiu Lan Zhao; Wei Min Deng; Yi Xin Liu; Jie Yang; Zhi Yao
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

4.  Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer.

Authors:  Hong Zhao Li; Yan Gao; Xiu Lan Zhao; Yi Xin Liu; Bao Cun Sun; Jie Yang; Zhi Yao
Journal:  Mol Cancer Res       Date:  2009-06-16       Impact factor: 5.852

Review 5.  The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs.

Authors:  Katherine Wu; Benjamin Bonavida
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

6.  Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.

Authors:  Stavroula Baritaki; Alina Katsman; Devasis Chatterjee; Kam C Yeung; Demetrios A Spandidos; Benjamin Bonavida
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

7.  BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma.

Authors:  Apostolos Zaravinos; Peggy Kanellou; Stavroula Baritaki; Benjamin Bonavida; Demetrios A Spandidos
Journal:  Cell Cycle       Date:  2009-05-26       Impact factor: 4.534

Review 8.  Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction.

Authors:  Jan Klysik; Steven J Theroux; John M Sedivy; Jeffrey S Moffit; Kim Boekelheide
Journal:  Cell Signal       Date:  2007-07-12       Impact factor: 4.315

9.  Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability.

Authors:  F Al-Mulla; S Hagan; W Al-Ali; S P Jacob; A I Behbehani; M S Bitar; A Dallol; W Kolch
Journal:  J Clin Pathol       Date:  2008-04       Impact factor: 3.411

10.  Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.

Authors:  Seung-Mo Hong; Ang Li; Kelly Olino; Christopher L Wolfgang; Joseph M Herman; Richard D Schulick; Christine Iacobuzio-Donahue; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

View more
  6 in total

1.  Clinicopathological features and prognostic implications of Raf kinase inhibitor protein downregulation in tongue squamous cell carcinoma.

Authors:  Fengchun Hu; Xiaohua Chen; Xiqiang Liu; Cheng Wang; Lanhai Lv; Nan Xie; Tianyi Wang; Hongzhang Huang
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

Review 2.  Metastasis suppressors in breast cancers: mechanistic insights and clinical potential.

Authors:  Christopher R Bohl; Sitaram Harihar; Warren L Denning; Rahul Sharma; Danny R Welch
Journal:  J Mol Med (Berl)       Date:  2013-12-06       Impact factor: 4.599

Review 3.  Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.

Authors:  Yantian Fang; Qizhi Yao; Zongyou Chen; Jianbin Xiang; Fisher E William; Richard A Gibbs; Changyi Chen
Journal:  Med Sci Monit       Date:  2013-10-31

4.  Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Eva Karamitopoulou; Inti Zlobec; Beat Gloor; Agathi Kondi-Pafiti; Alessandro Lugli; Aurel Perren
Journal:  J Transl Med       Date:  2013-12-14       Impact factor: 5.531

5.  RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling.

Authors:  Zi-Hao Qi; Hua-Xiang Xu; Shi-Rong Zhang; Jin-Zhi Xu; Shuo Li; He-Li Gao; Wei Jin; Wen-Quan Wang; Chun-Tao Wu; Quan-Xing Ni; Xian-Jun Yu; Liang Liu
Journal:  Int J Oncol       Date:  2018-02-07       Impact factor: 5.650

6.  MicroRNA-18a induces epithelial-mesenchymal transition like cancer stem cell phenotype via regulating RKIP pathway in pancreatic cancer.

Authors:  Honggang Kang; Dan Ma; Jing Zhang; Jun Zhao; Mengxiang Yang
Journal:  Ann Transl Med       Date:  2020-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.